Home › Trial NCT05606380
A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
- Trial IDNCT05606380
- StatusUnknown
- PhasePhase 1
- Study typeInterventional
- SponsorShanghai Henlius Biotech
- Enrollment11
- Start date2022-12-02
- ConditionsSolid Tumor and Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.